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Introduction
Aging is the most powerful influence and risk factor for several neurodegenerative diseases, including Parkinson's disease (PD) . Genetic links to PD are well-described giving rise to monogenic forms of the disease (such as involving SNCA, parkin and LRRK2 genes (Kumaran and Cookson, 2015) , as well as identification of high-risk gene variants such as mutations in GBA (Sidransky et al., 2009) , and risk factor genes for idiopathic PD from GWAS meta-analyses (Kumaran and Cookson, 2015) . The connection between aging and genetic links to PD is not well understood, but one interesting hypothesis to test is whether cell biological processes associated with aging phenocopy the pathophysiological changes that occur in some forms of the disease that have a genetic cause.
One of the most common genetic risk factors of PD identified to date are mutations causing haploinsufficiency in GBA, the gene encoding glucocerebrosidase (GCase). GCase is a lysosomal hydrolase responsible for the metabolism of the GSLs glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph). GCase activity is reduced in several brain regions of PD patients carrying a GBA mutation (Gegg et al., 2012) . In addition, compared to healthy controls, brain GCase activity is also reduced in sporadic PD patients without a GBA mutation, together with an increase in GlcSph substrate levels. A loss of GCase enzymatic activity in PD is also reflected in the blood and CSF of patients (Alcalay et al., 2015; Parnetti et al., 2017 ). An age-dependent reduction in brain GCase activity is measured in healthy subjects in the brain regions most affected in PD, and by the time an individual reaches the 7 th -8 th decade of life, GCase activity in the substantia nigra and putamen are reduced to the same extent as subjects with sporadic PD (Rocha et al., 2015a) . The potential implication of these findings is that haploinsufficiency of GBA is not only phenocopied in non-hereditary forms of PD but also by the process of aging. With respect to changes in GSLs in the human brain during aging, previous reports have indicated alterations to several complex gangliosides in multiple brain regions, including reduced GM1a and GD1a (Kracun et al., 1991; Svennerholm et al., 1994) . In normal aging in mice, or in models of accelerated senescence, measurements of brain ganglioside content have indicated increased GM1a, and reduced levels of GD1a, GD1b, GT1b (Ohsawa, 1989; Ohsawa and Shumiya, 1991) . The processes underlying normal brain aging involve cellular organelles, including mitochondria. Aging is associated with accumulation of mitochondrial DNA (mtDNA) mutations in substantia nigra dopaminergic neurons (Kraytsberg et al., 2006) . Several PD associated gene mutations have been shown to impair mitochondrial function, including PINK1
and parkin which are involved in mitochondrial quality control and mitophagy (Nguyen et al., 2016) . It is therefore conceivable that with age, changes to multiple cell biological pathways, such as those associated with lysosomal function, GSL homeostasis, and mitochondrial integrity, may lead to cell dysfunction in vulnerable neurons and lower the threshold for developing PD and may represent new therapeutic targets.
Following up on our findings of an age-dependent reduction in GCase activity and an elevation of some GSLs in PD patients and aging control cases, and in human PD patient iPSC neurons (Mazzulli et al., 2016; Rocha et al., 2015c) , we asked whether PD-and aging-induced changes to lysosomal GCase activity and GSL homeostasis in the brain could be reflected in other nonhuman mammalian systems. In the present study, we demonstrate that aging in the mouse brain results in a similar lipid profile to that seen in the aging human brain and in PD, with elevated levels of glucosylceramide, glucosylsphingosine, lactosylceramide and GM1a, and decreased levels of GD1a, GD1b and GT1b. These data are important for understanding normal brain aging and potentially also challenge the popular view that proteinopathy is the only trigger for neuronal M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 demise in PD, since altered GSL homeostasis may parallel or even precede changes in protein aggregation. These findings may have relevance for understanding pathophysiological mechanisms in age-associated neurodegenerative diseases.
Results
Accumulation of glucosylceramide and glucosylsphingosine in the brain of mice during normal aging Whole brain homogenates from wildtype (WT) BDF1 mice were collected at 2 and 12 months of age and LC-MS/MS analysis was used to measure levels of the GSLs, GlcCer and GlcSph ( Figure 1A) . A significant increase in both GlcCer (147.3±5.8%, p<0.01) and GlcSph (175.4±16.1%, p<0.01) was observed in the brains of 12-month old animals compared to 2month old animals ( Figure 1B , C). Next, to establish whether the aging-induced increase in GlcCer was also observed in a different inbred mouse strain, whole brain homogenates from FVB/N mice between 1.5 and 24 months of age were utilized for NP-HPLC analysis of GlcCer.
Increasing age was significantly correlated with GlcCer levels (r = 0.8095, p<0.001) ( Figure 1D ).
In mice at 17-24 months, GlcCer levels were increased to 163.8% of young mice aged 1.5-3 months ( Figure 1E ) (p<0.001, unpaired t test).
Levels of lactosylceramide and complex gangliosides are associated with normal aging of the mouse brain
To assess whether aging induced a selective increase in brain GlcCer and GlcSph, levels of lactosylceramide and complex gangliosides were measured. Brain LacCer was also significantly correlated with age ( Figure 1F r=0.6832, p<0.0001) in FVB/N mice. At 17-24 months of age levels of LacCer were 148.7% of levels detected at 1.5-3 months (p<0.001) ( Figure 1G ).
The major GSLs found in the mammalian nervous system are GM1a, GD1a, GD1b and GT1b.
Levels of GM1a were significantly increased with age in mouse brain (Figure 2A , p<0.001, unpaired t-test) . Conversely, GD1a, GD1b and GT1b levels were all negatively correlated with age ( Figure 2C , E, G) (GD1a: r= -0.6494, p<0.0001; GD1b: r= -0.3624, 0<0.01;
GT1b: r= -0.7519, p<0.0001). In mice at 17-24 months of age, GD1a, GD1b and GT1b were all significantly reduced compared to mice at 1.5-3 months of age ( Figure 2D , F, H) (GD1a: 74.9% cf. young mice, p< 0.001, unpaired t-test; GD1b: 86.5% cf. young mice, p<0.001, unpaired t-test;
GT1b: 55.6% cf. young mice, p<0.001, unpaired t-test).
Total brain GSL load is increased with age in mice
In order to evaluate whether total brain GSL load was changed with age, GlcCer, LacCer and ganglioside levels were summed ( Figure 3 ). Total GSLs were significantly correlated with age (r=0.7887, p<0.001) ( Figure 3A ), and total GSLs in 17-24 months old FVB/N mice were 136.8% of those measured in 1.5-3 months old animals (p<0.001, unpaired t-test) ( Figure 3B ).
Age-dependent changes to GSLs are conserved across different strains of wildtype mice
To assess whether the increase in GlcCer and GM1a and the decrease in GD1b, GT1b and GD1b in brain during aging is a phenomenon specific for WT FVB/N mice, we performed lipidomic analysis of whole brain homogenates of wildtype BALB/c mice at 1-2 months and 20-21 months of age and wildtype C57BL/6-DBA/2-BDF1 mice at 3-4 months and 17-18 months of age.
In accordance with previous results, a significant increase in GlcCer and LacCer in both strains was observed in the brains of old animals compared to young animals ( Figure 4A , B and 5A, B) (GlcCer: p<0.0001 and p=0.0021, LacCer: p<0.0001 and p=0.0059, unpaired t-test). Levels of GM1a were significantly increased with age in mouse brain of both strains ( Figure 4C and 5C, p<0.0001 and p<0.0001, respectively, unpaired t-test). Conversely, in old mice, GD1a, GD1b
and GT1b were all significantly reduced compared to young mice ( Figure 4D , E, F and 5D, E, F) (GD1a: p<0.0001 and p=0.0237, GD1b: p=0.0005 and p=0.1011; GT1b: p<0.0001 and p=0.0176). To evaluate whether total brain GSL load was changed with age, GlcCer, LacCer and ganglioside levels were summed. The level of total GSLs in 20-21 months old BALB/c mice was increased to 163% of those measured in 1-2 months old animals ( Figure 4G , p<0.0001). Total GSLs in 17-18 months old C57BL/6-DBA/2-BDF1 mice were increased to 127.6% of those measured in 3-4 months old animals ( Figure 5G , p=0.0017).
In summary, age-dependent changes to GSLs are conserved across different strains of wildtype mice.
Reduced glucocerebrosidase and increased neuraminidase activity in the brain of aged mice Not all GSLs are necessarily exclusively formed from de novo biosynthesis as they recycle and can be remodeled by neuraminidases. It is interesting to note that the increase in GM1a may likely be a result of sequential removal of sialic acid residues from GD1a, GD1b and GT1b by neuraminidases, explaining their selective concomitant reduction with aging. Consequently, the activities of various lysosomal hydrolases were assayed in whole brain homogenates of 3-month and 24-month old WT FVB mice (n=4 per age). A significant decrease in GBA β−glucosidase (GCase) activity was observed in brain homogenates of 24-month old WT FVB/N mice compared to 3-month old WT FVB/N mice ( Figure 6A , p=0.0007, unpaired t-test, 17% reduction at 24 months vs. 3 months). In addition, a significant decrease in GBA2 β−glucosidase activity was observed in brain homogenates of aged WT FVB/N mice compared to young WT FVB/N mice ( Figure 6B , p=0.0292, unpaired t-test, 13% reduction at 24 months vs. 3 months). There
was no difference in α-galactosidase or β-hexosaminidase activity in brain homogenates of 3month and 24-month old WT FVB/N mice ( Figure 6C , D). Also, a significant decrease in β−galactosidase activity was observed in brain homogenates of 24-month old WT FVB/N mice compared to 3-month old WT FVB/N mice ( Figure 6E , p=0.0103, unpaired t-test, 12% reduction at 24 months vs. 3 months). Furthermore, a significant increase in neuraminidase activity was observed in brain homogenates of old WT FVB/N mice compared to young WT FVB mice ( Figure 6F , p=0.0247, unpaired t-test, 38% increase at 24 months vs. 3 months). Importantly, we verify these changes in two independent mouse strains, BALB/c and BDF1 (data not shown).
Aged mice display markers of proteasomal dysfunction
To correlate age-dependent changes in lipid homeostasis to the level of protein, young-and aged mouse whole-brain homogenates were lysed and probed for a variety of proteolytic markers ( Figure 7 ). Though the steady-state markers of autophagy, LC3 and SQSTM1/p62, were unchanged between and young and aged mice ( Figure 7D , E), we found significant increases in levels of LAMP2A ( Figure 7C , 30±12%, p<0.05) and polyubiquitin ( Figure 7B , 95±25%, p<0.05, and 74±13%, p<0.01, respectively).
Discussion
Aging is the most important risk factor for developing PD, and brain GCase activity is reduced over time in normal aging in humans (Rocha et al., 2015a) . Aging mirrors changes to the GBA pathway similar to those that occur in genetic (GBA haploinsufficiency) and sporadic (nonGBA) forms of PD, and our previous data from human substantia nigra demonstrated that GCase activity is reduced and levels of GlcSph are increased in sporadic PD (Rocha et al., 2015a) . In
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10 the present study, we provide evidence that decreased GCase activity and increased lipid load, as observed in brains of sporadic PD patients, also occurs in normal aging in mouse brain. We hypothesize that the increased GSL load associated with aging of the brain accelerates degenerative processes in vulnerable neurons, such as midbrain dopaminergic neurons, and lowers the threshold for developing PD (Rocha et al., 2015a) . Critically, this hypothesis challenges the prevailing view that proteinopathy is the primary cause of PD since lipids and lysosomal changes could precede or exacerbate the protein load and aggregation.
Our data shows that total GSL levels are progressively increased in the aging mouse brain, including elevations in levels of GlcCer, LacCer and GM1a. These changes to GSLs are accompanied by a reduction in the activity of GBA and GBA2, as well as β-galactosidase, whereas lysosomal β-hexosaminidase and α-galactosidase activities were unaffected, and neuraminidases were increased. GBA (GCase) activity is decreased in the brain in aging in humans, as well as in sporadic PD (Rocha et al., 2015a) , and reduced activity of both GCase and β-galactosidase are reported in human neurons from PD patients carrying a GBA mutation (Schondorf et al., 2014) . Future studies will determine the possible antecedent cellular mechanism(s) underlying changes in lysosomal hydrolases in the aging brain, as well as identify whether specific brain regions relevant to neurodegeneration are affected.
GlcCer is the biosynthetic precursor of all more complex GSLs and the final product of GSL catabolism in the lysosome. It is markedly elevated in the brain in human neuronopathic Gaucher disease (GD) and related experimental models (Nilsson and Svennerholm, 1982; Rocha et al., 2015c) . This increase in GlcCer is associated with neuropathological changes in neurons and Farfel-Becker et al., 2014) . GCase deficiency in neuronopathic GD also causes accumulation of GlcSph, which is the deacylated form of GlcCer. Our data showed that both GlcCer and GlcSph levels in brain were increased between 2 and 12 months of age in BDF1 wildtype mice. GlcSph levels have been shown to be directly neurotoxic (Schueler et al., 2003) and are correlated with CNS involvement in GD patients (Orvisky et al., 2002) . Although genetic and pathological links between GD and PD are well documented (Sidransky et al., 2009) , the case for a general lysosomal capacity loss associated with increased risk for PD is supported by links between parkinsonism and/or α-synucleinopathy and other lysosomal storage disorders including GM1 gangliosidosis (Roze et al., 2005) , Niemann-Pick disease Type C (Saito et al., 2004) , Fabry disease (Buechner et al., 2006) and Krabbe disease (Smith et al., 2014) . In adultonset GM1 gangliosidosis, which is caused by β-galactosidase deficiency inducing CNS accumulation of ganglioside GM1a, patients present with generalized dystonia associated with akinetic-rigid parkinsonism (Roze et al., 2005) . Our current data shows that β-galactosidase activity in brains of aged mice is decreased and GM1a levels are increased in normal aging in mice. GM1a levels are increased in lipid rafts in synaptosomes in aged animals (Yamamoto et al., 2008) , and interestingly in early PD, nigrostriatal degeneration is thought to occur in a retrograde manner with synaptic terminals affected first (Chung et al., 2009) . Links between GM1a and the dopaminergic system also suggest that a loss of GM1a is associated with PD-like pathophysiological changes (Wu et al., 2012) . GM1a is involved in signaling of the neurotrophic factor, GDNF (Hadaczek et al., 2015) , and elevated levels of GM1a, as we observed with murine aging, could represent an age-related compensatory mechanism to enhance neurotrophic activity.
Interestingly, pharmacological supplementation of PD patients with GM1a has been shown to have beneficial effects on clinical motor and neuropsychological functions in a 5-year study M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 12 (Schneider et al., 2010) . Curiously, in addition to having essential functions in membrane lipid rafts (Schnaar, 2016) , GM1a is enriched in myelin (Heinecke et al., 2015) and the GM1a increase observed here may reflect age-related changes in myelin structures.
The association of lysosomal storage disorders and parkinsonism, and normal aging and GSL accumulation observed here in mice, is intriguing for understanding the pathophysiology of agerelated diseases and it suggests a complex interaction between multiple GSLs, aging and neurodegeneration. Indeed, the principal risk factor for developing most adult onset neurodegenerative diseases including PD is aging (Niccoli and Partridge, 2012) . Specific mechanisms related to aging in PD have been obscured for many years in the literature by very limited clinical pathological human studies (Fearnley and Lees, 1991) and only recently a broader and more accurate perspective has been provided showing the precise neuropathological resemblance between PD and aging in human and primate brain -in fact, there is selective vulnerability of midbrain substantia nigra A9 dopamine neurons in both PD and normal aging (Cabello et al., 2002; Collier et al., 2011; Ma et al., 1999; McGeer et al., 1977; Rodriguez et al., 2015; Rudow et al., 2008) . The age-dependent reduction of nigral dopamine neurons is conserved between species and in the substantia nigra pars compacta (SNpc) of wildtype mice, a reduction of ~10% dopaminergic neurons is observed between 7-25 months of age (Lee et al., 2016) . It is not known what drives age-related decline and original theories suggested that the cellular mechanisms associated with aging of midbrain dopamine (and other vulnerable) neurons and PD were unrelated. However, it has become apparent that normal aging in animals and (Collier et al., 2011) . We have previously shown that accumulation of GlcSph occurs in several brain regions in sporadic PD (Rocha et al., 2015a) , however, the selective vulnerability of the midbrain A9 dopamine neurons in PD exemplifies that this population of neurons may be particularly vulnerable to GSL accumulation. The elevations of GSLs found in normal aging are not associated with the same degree of storage and neuronal death observed in neuronopathic GD and other lysosomal storage disorders, but given that the current analyses represent whole brain homogenates, individual cell types may show greater fold differences. Further studies will determine GSL and enzymatic alterations in young and aged mice in individual brain regions affected in PD and other age-related neurodegenerative disorders. It is reasonable to expect that moderate elevations of GSLs would be associated with multiple pathophysiological consequences and disrupted neuronal function. In their functional roles, GSLs are located in cellular membranes, cluster in lipid rafts, and are involved in cell-cell recognition, regulation of signal transduction, and protein cargo sorting (Lingwood, 2011) .
Indeed, many membrane-associated receptor and non-receptor proteins are influenced by the lipid microenvironment. A moderate accumulation of GSLs and changes in the relative amounts of GSLs in aging could have marked physiological effects on these cellular functions. Whereas levels of GlcCer, LacCer and GM1a are increased with age, our present data also shows significant reductions in the levels of GD1a, GD1b and GT1b. Not all GSLs are necessarily exclusively formed from de novo biosynthesis as they recycle and can be remodeled by neuraminidases. Indeed, our data demonstrates that neuraminidase activity is increased in aged mice, and this may account for the observed age-related increase in GM1a and concomitant reduction in GD1a, GD1b and GT1b through sequential removal of sialic acid residues.
Conversely, we have previously shown that genetic deficiency of neuraminidases 3 and 4 in mice M A N U S C R I P T
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14 causes a reduction in levels of GM1a (Pan et al., 2017) . Our findings on altered ganglioside levels with aging are consistent with earlier reports describing similar patterns of changes both in aging mouse brain (Ohsawa, 1989) , and in a mouse model of accelerated senescence (Ohsawa and Shumiya, 1991) . Reductions in GM1a, GD1a, GD1b and GT1b have been reported in the frontal and temporal cortices, and in the basal telencephalon of patients with Alzheimer's disease, another age-associated disease, compared to the same area of control patients (Kracun et al., 1991) . Our current data indicating disrupted balance in GSL composition in aging is therefore potentially relevant for determining underlying disease mechanisms not only in PD but also in several age-related neurodegenerative disorders.
The cellular processes altered by pathologically increased GSLs can provide mechanistic clues for treatment and prevention of age-related neurodegenerative disease. There is evidence for lysosomal dysfunction, impairment of autophagy and UPS protein degradation pathways, disrupted calcium homeostasis, mitochondrial dysfunction and oxidative stress, in several lysosomal storage disorders (Platt et al., 2012) , and these perturbations are also common to agerelated neurodegenerative disorders including PD (Reeve et al., 2014) . Moreover, there is considerable evidence for an association between GSL metabolism and α-synuclein, a key pathogenic protein in PD (Rocha et al., 2015b; Rocha et al., 2015c; Sardi et al., 2017; Taguchi et al., 2017) . A recent report demonstrates that Lewy bodies and Lewy neurites, which contain αsynuclein and are pathological hallmarks of PD, are also enriched in lipids, membrane fragments and distorted organelles (Shahmoradian et al., 2017) . We have previously shown that modulating the activity of GCase in rodents causes inverse changes in α-synuclein accumulation, such that reducing GCase activity (with a concomitant elevation of GlcCer and GlcSph) increases α-M A N U S C R I P T
15 synuclein high molecular weight (HMW) species and aggregation, whereas elevation of GCase through gene delivery reduces α-synucleinopathy and protects dopamine neurons from degeneration in the rodent substantia nigra (Rocha et al., 2015b; Rocha et al., 2015c) .
This work has important implications for developing novel therapeutics for age-related neurodegenerative disorders. We hypothesize that aging-induced changes in GSLs will accelerate degenerative processes in vulnerable neurons in neurodegenerative disorders; such changes can potentially be targeted by effective interference in relevant enzymatic pathways, either using gene delivery to increase the hydrolysis of substrates, using small molecules to decrease GSL biosynthesis (using substrate reduction therapy) or pharmacological chaperones that facilitate transport of lysosomal hydrolases to the lysosomal compartment. Indeed such strategies are already in use or are being developed clinically in several lysosomal storage disorders (Cox, 2015; Platt and Jeyakumar, 2008) .
In conclusion, these new data show that normal aging alters several GSLs in the mammalian brain, including an elevation of GlcCer, LacCer, GM1a and total GSL content, and selective reductions in GD1a, GD1b and GT1b gangliosides. Importantly, changes in some GSLs in aging appear to be conserved between mice and humans and resemble the changes observed in sporadic PD. This may allow the identification of rational treatments to normalize these altered patterns of GSL expression. P8088558D) from the UK Home Office. Animals were housed according to standard conditions, in a dark/light cycle of 12 hour, with ad libitum access to food and water. Male and female FVB mice at 1.5-24 months of age (The Jackson Laboratory, Bar Harbor, USA) (n=20 male and n=36 female) and male BDF1 (mixed C57/BL/6-DBA-2 background) mice at 2-12 months of age (Charles River, Wilmington, USA) (n=4, 2 months; n=6, 12 months) were used. Furthermore, a separate cohort of BDF1 male mice at 3-4 months (n=6) and 17-18 months (n=7) of age, and of male and female BALB/c mice at 1-2 months (n=13) and 20-21 months (n=9) of age (The Jackson Laboratory, Charles River, UK) were used. Mice were terminally anesthetized by intraperitoneal injection of sodium pentobarbital (130mg/kg) and intracardially perfused with heparinized saline. Brains were rapidly removed, homogenized in water using a handheld Polytron® homogenizer and aliquoted before being snap frozen and stored at -80 o C.
NP-HPLC analysis
GlcCer and downstream GSLs were analysed essentially as described by Neville and coworkers (Neville et al., 2004) . Lipids from brain homogenates were extracted with chloroform:methanol 
LC-MS/MS analysis
Quantification of GlcCer and GlcSph tissue levels using liquid chromatography / tandem mass spectrometry (LC-MS/MS) in aliquots of brain homogenates from BDF1 mice was performed as previously described (Rocha et al., 2015c) . Briefly, brains were homogenized in water at a ratio of 14mg wet weight tissue per 50µL water, and GlcCer and GlcSph were extracted from the tissue homogenate in 800uL of solvent. Samples were sonicated, vortexed and centrifuged before the supernatant was transferred to an injection plate for LC-MS/MS analysis. Pearson correlation analysis (A) of the sum of GlcCer + LacCer + GM1a + GD1a + GD1b + GT1b levels in whole brain homogenates from WT FVB mice at 1.5-24 months of age shows that normal aging in mice is associated with increased load of GSLs with age. (B) Comparison of total GSL levels in young (1.5-3 months, n=16) vs. old (17-24 months, n=7) (*** = p<0.001, unpaired t-test). 
